Assessment of Corneal Sensation, Innervation and Retinal Nerve Fiber Layer in Patients Treated with Multiple Intravitreal Ranibizumab Injections

Purpose To evaluate the effects of repeated intravitreal ranibizumab injections on corneal sensitivity, corneal sub-basal nerve plexus (SBNP) and peripapillary retinal nerve fiber layer (RNFL) thickness in patients with neovascular age-related macular degeneration (AMD). Methods Sixty-six eyes of 33 patients who had received unilateral repeated intravitreal ranibizumab injections (0.5 mg/0.05 ml) for the treatment of AMD and 25 eyes of 25 healthy subjects were included in the study. Central corneal sensation was measured using the contact Cochet-Bonnet esthesiometer. The laser scanning in vivo corneal confocal microscope was used to determine corneal SBNP parameters. The peripapillary RNFL thickness was assessed with spectral-domain optical coherence tomography. Data obtained from the ranibizumab-injected eyes were compared with those of the fellow non-treated eyes and the eyes of the healthy control subjects. Results The mean number of ranibizumab injections per eye was 8.9±5.0 (range 3–20). There were no statistically significant differences in the central corneal sensitivity threshold and corneal SBNP parameters between the ranibizumab-injected eyes and the fellow untreated eyes or between those with neovascular AMD and the healthy control group (P>0.05 for all). The average peripapillary RNFL thickness of the treated eyes did not differ significantly to the fellow eyes (P = 0.237), and the eyes of healthy control subjects (P = 0.918). There were no significant correlations between the number of ranibizumab injections and any of the study parameters. Conclusions Multiple intravitreal injections of ranibizumab seem to have no harmful effects on corneal sensitivity, innervation and peripapillary RNFL thickness in patients with AMD.

[1]  Ş. Gedik,et al.  The effect and safety of intravitreal injection of ranibizumab and bevacizumab on the corneal endothelium in the treatment of diabetic macular edema , 2017, Cutaneous and ocular toxicology.

[2]  M. Kucukevcilioglu,et al.  Peripapillary RNFL thickness in nonexudative versus chronically treated exudative age-related macular degeneration. , 2016, Canadian journal of ophthalmology. Journal canadien d'ophtalmologie.

[3]  M. Ohji,et al.  Ranibizumab and Aflibercept: Intraocular Pharmacokinetics and Their Effects on Aqueous VEGF Level in Vitrectomized and Nonvitrectomized Macaque Eyes. , 2015, Investigative ophthalmology & visual science.

[4]  S. Harper,et al.  Vascular endothelial growth factor-A165b prevents diabetic neuropathic pain and sensory neuronal degeneration. , 2015, Clinical science.

[5]  D. Denis,et al.  Effects of multiple intravitreal anti-VEGF injections on retinal nerve fiber layer and intraocular pressure: a comparative clinical study. , 2014, International journal of ophthalmology.

[6]  Hyewon Chung,et al.  Change of retinal nerve fiber layer thickness in various retinal diseases treated with multiple intravitreal antivascular endothelial growth factor. , 2014, Investigative ophthalmology & visual science.

[7]  M. Rosenblatt,et al.  Vascular endothelial growth factor promotes anatomical and functional recovery of injured peripheral nerves in the avascular cornea , 2013, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[8]  G. Sobacı,et al.  Effects of multiple intravitreal anti-VEGF injections on retinal nerve fiber layer and intraocular pressure: a comparative clinical study. , 2013, International journal of ophthalmology.

[9]  J. García-Feijóo,et al.  Retinal nerve fiber layer thickness changes in patients with age-related macular degeneration treated with intravitreal ranibizumab. , 2012, Investigative ophthalmology & visual science.

[10]  J. Graham,et al.  Automatic analysis of diabetic peripheral neuropathy using multi-scale quantitative morphology of nerve fibres in corneal confocal microscopy imaging , 2011, Medical Image Anal..

[11]  C. Smith,et al.  IL-17 and VEGF are necessary for efficient corneal nerve regeneration. , 2011, The American journal of pathology.

[12]  Michael B Horsley,et al.  Retinal nerve fiber layer thickness in patients receiving chronic anti-vascular endothelial growth factor therapy. , 2010, American journal of ophthalmology.

[13]  H. Helbig,et al.  Lack of therapeutic effect of ranibizumab in fellow eyes after intravitreal administration. , 2010, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[14]  B. Lubin,et al.  © 2009 Molecular Vision , 2022 .

[15]  A. Rouvas,et al.  The Effect of Intravitreal Ranibizumab on the Fellow Untreated Eye with Subfoveal Scarring due to Exudative Age-Related Macular Degeneration , 2009, Ophthalmologica.

[16]  Judy E. Kim,et al.  Short-term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents. , 2008, American journal of ophthalmology.

[17]  Magali Saint-Geniez,et al.  Endogenous VEGF Is Required for Visual Function: Evidence for a Survival Role on Müller Cells and Photoreceptors , 2008, PloS one.

[18]  Min Zhang,et al.  Vascular endothelial growth factor mediates corneal nerve repair. , 2008, Investigative ophthalmology & visual science.

[19]  H. Hollands,et al.  Short-term intraocular pressure changes after intravitreal injection of bevacizumab. , 2007, Canadian journal of ophthalmology. Journal canadien d'ophtalmologie.

[20]  J. Pulido,et al.  Pharmacokinetics of intravitreal ranibizumab (Lucentis). , 2007, Ophthalmology.

[21]  David T. Shima,et al.  Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. , 2007, The American journal of pathology.

[22]  Philip J Rosenfeld,et al.  Ranibizumab for neovascular age-related macular degeneration. , 2006, The New England journal of medicine.

[23]  I. Zachary.  Neuroprotective Role of Vascular Endothelial Growth Factor: Signalling Mechanisms, Biological Function, and Therapeutic Potential , 2005, Neurosignals.

[24]  D. Fei,et al.  Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration. , 2005, Investigative ophthalmology & visual science.

[25]  R. Klein,et al.  Causes and prevalence of visual impairment among adults in the United States. , 2004, Archives of ophthalmology.

[26]  R. A. Malik,et al.  Corneal confocal microscopy: a non-invasive surrogate of nerve fibre damage and repair in diabetic patients , 2003, Diabetologia.

[27]  M. Vitek,et al.  Vascular endothelial growth factor rescues hippocampal neurons from glutamate‐induced toxicity: signal transduction cascades , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[28]  G. Lundborg,et al.  Vascular Endothelial Growth Factor Has Neurotrophic Activity and Stimulates Axonal Outgrowth, Enhancing Cell Survival and Schwann Cell Proliferation in the Peripheral Nervous System , 1999, The Journal of Neuroscience.

[29]  P. D. de Jong,et al.  Increased expression of angiogenic growth factors in age-related maculopathy , 1997, The British journal of ophthalmology.

[30]  S. Seregard,et al.  Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. , 1996, Investigative ophthalmology & visual science.

[31]  K. Tsubota,et al.  Decrease in Corneal Sensitivity and Change in Tear Function in Dry Eye , 1996, Cornea.

[32]  F. Ferris,et al.  Age-related macular degeneration and blindness due to neovascular maculopathy. , 1984, Archives of ophthalmology.

[33]  C. Meyer,et al.  Intraocular pharmacokinetics of bevacizumab following a single intravitreal injection in humans , 2012 .

[34]  Philip J Rosenfeld,et al.  A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. , 2009, American journal of ophthalmology.

[35]  P. Carmeliet,et al.  VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death , 2003, Nature Genetics.

[36]  B. Dhillon,et al.  Clinical Ophthalmology Dovepress Evaluation of the Effect of Intravitreal Ranibizumab Injections in Patients with Neovascular Age Related Macular Degeneration on Retinal Nerve Fiber Layer Thickness Using Optical Coherence Tomography Gerassimos Lascaratos , 2022 .